

URGENT DRUG RECALL

August 6, 2026

Dear Healthcare Provider or Distributor:

Baxter Healthcare Corporation is issuing an Urgent Drug Recall for the lots of drug products listed in the enclosed Attachment A due to the potential of contamination with a beta-lactam drug product. The affected lot numbers were distributed from 2/3/2025 to 7/29/2026 in the United States.

Affected Product – Please refer to Attachment A

Hazard Involved

Products containing beta-lactam compounds may cause allergic reactions, including life-threatening reactions, in individuals allergic to beta-lactam compounds. To date, Baxter has not confirmed any beta-lactam contamination in distributed non-beta-lactam product nor received any reports of adverse events related to this issue.

Actions to be Taken by Customers

1. Immediately locate, isolate, and cease all use of the affected lot numbers of the product. The product code, lot number, and expiration date can be found on the individual product and shipping carton. See enclosed Attachment B for product label photos to assist in identifying the product at the healthcare provider level.
2. Contact Baxter Healthcare Center for Service to arrange for return and replacement product at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday. Please have your Baxter 8-digit ship-to account number, product code, lot number, and quantity of product to be returned ready when calling.
3. If you received this communication directly from Baxter, please acknowledge receipt of this notification by following the instructions on the enclosed reply instruction sheet, even if you have no remaining inventory. Acknowledging receipt will prevent you from receiving repeat notices. If you do not complete the acknowledgement, you will receive a phone call from Accenture LLP on behalf of Baxter to confirm your receipt of this notification.
4. If you purchased this product from a distributor or wholesaler, please contact them to arrange for return of the affected product. Please note that responding to Baxter is not applicable. If a response is requested by your distributor or wholesaler, please respond to them according to their instructions.
5. Please forward a copy of this communication to the director of pharmacy, director of nursing, director of purchasing, facility risk manager, and any other departments within your institution who use the affected product.
6. If you are a dealer, wholesaler, distributor/reseller, or original equipment manufacturer (OEM) that distributed any affected product to other facilities, please conduct a user-level recall of the affected product that you distributed to customers and check the associated box on the customer portal.

Further Information and Support

For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday.

The United States Food and Drug Administration (FDA) has been notified of this action. Any product quality complaints or adverse events experienced with the use of these products may be reported using one of the following options:

- Contacting Baxter Product Surveillance at the Baxter product feedback portal at <https://productfeedback.baxter.com>, or emailing Baxter at corporate_product_complaints_round_lake@baxter.com
- Reporting to the FDA MedWatch Serious Injury Reporting Program:
 - o **Online:** By completing and submitting the report at www.accessdata.fda.gov/scripts/medwatch
 - o **Regular mail or Fax:** Download the form from www.fda.gov/MedWatch/getforms.htm or call 800-332-1088 to request a reporting form, then complete and mail it to the address on the pre-addressed form or submit by fax to 800-332-0178

We apologize for any inconvenience this may cause you and your staff.

Sincerely,



Craig Plunkard
Senior Director, Quality
Baxter Healthcare Corporation

Enclosure: Baxter Reply Instruction Sheet
Attachment A: Affected Lot Numbers
Attachment B: Affected Product Label Photos

Attachment A: Affected Lot Numbers

Product Code	Product Description	Lot Number	Expiration Date	NDC Number
2G3322	MYXREDLIN (insulin human in 0.9% sodium chloride), 100 units/ 100 mL (1 unit/mL) in a single-dose container, for intravenous use.	NC188630	12/31/2027	0338-0126-12
		NC188708	12/31/2027	
		NC188791	12/31/2027	
		NC188845	12/31/2027	
		NC188876	12/31/2027	
		NC188968	12/31/2027	
		NC193719	4/30/2028	
		NC193849	4/30/2028	
		NC194051	5/31/2028	
		NC194105	5/31/2028	
		NC195171	6/30/2028	
2G3424	Famotidine Injection Iso-osmotic Sodium Chloride Premix, 20 mg/50 mL in GALAXY Plastic Container. Liquid Premix.	NC188586	2/28/2027	0338-5197-41
		NC188913	3/9/2027	
2G3444	CARDENE IV (nicardipine hydrochloride) injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL) in GALAXY Plastic Container. Liquid Premix.	NC177818	12/31/2026	43066-016-10
		NC188869	12/31/2027	
2G3450	NEXTERONE (amiodarone HCl, USP) Premixed Injection 360 mg/200 mL (1.8 mg/mL) in GALAXY Container. Liquid Premix. Single Dose Ready- to-use, sterile, nonpyrogenic, iso-osmotic solution (in Dextrose).	NC177832	12/31/2026	43066-360-20
		NC185417	8/31/2027	
		NC185455	8/31/2027	
		NC188593	11/30/2027	
		NC188647	12/31/2027	
		NC188685	12/31/2027	
		NC188807	12/31/2027	
		NC188838	12/31/2027	
		NC188920	12/31/2027	
		NC193603	4/30/2028	
		NC193726	4/30/2028	
		NC193788	4/30/2028	
		NC193863	4/30/2028	
		NC193900	4/30/2028	
		NC194082	5/31/2028	
		NC194112	5/31/2028	
		NC194143	5/31/2028	
		NC195157	5/31/2028	
2G3453	Clindamycin Injection USP in 5% Dextrose, 600 mg/50 mL in GALAXY Plastic Container. Liquid Premix	NC193764	10/18/2027	0338-3612-50
		NC195232	11/25/2027	
2G3454	Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL in GALAXY Plastic Container. Liquid Premix.	NC185424	2/12/2027	0338-3814-50
		NC185479	2/13/2027	
		NC193948	10/23/2027	
2G3456	Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg/50 mL in GALAXY Plastic Container. Liquid Premix.	NC193689	10/16/2027	0338-9549-50
2G3459	Clindamycin Injection USP in 5% Dextrose 900 mg/50 mL (18 mg/mL) in GALAXY 50 mL Single Dose Container	NC194075	10/29/2027	0338-4114-50
2G3467	Clindamycin Injection USP in 5% Dextrose 900 mg/50 mL (18 mg/mL) in GALAXY 50 mL Single Dose Container.	NC194068	10/29/2027	43066-995-24


Attachment A: Affected Lot Numbers

Product Code	Product Description	Lot Number	Expiration Date	NDC Number
2G3497	Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride injection, 400 mcg/100 mL (4 mcg/mL) in GALAXY Container. Liquid Premix.	NC188654	8/31/2027	0338-9557-12
		NC188821	9/30/2027	
		NC193658	1/31/2028	
		NC193702	1/31/2028	
2G3498	Vasopressin in 0.9% Sodium Chloride Injection, 20 units / 100mL (0.2 units / mL) Single-Dose Infusion Bag, Liquid Premix	NC193672	4/30/2028	0338-9640-12
		NC193795	4/30/2028	
		NC194198	5/31/2028	
2G3499	Vasopressin in 0.9% Sodium Chloride Injection, 40 units / 100mL (0.4 units / mL) Single-Dose Infusion Bag, Liquid Premix	NC185448	8/31/2027	0338-9647-12
		NC192910	4/30/2028	
		NC195218	6/30/2028	
2G3552	Vancomycin Injection, USP in 5% Dextrose, 1 gram/200 mL in GALAXY Plastic Container. Frozen Premix.	NC188678	12/1/2026	0338-3552-48
		NC188814	12/5/2026	
		NC188944	12/8/2026	
		NC193610	4/21/2027	
		NC193665	4/23/2027	
2G3581	Pantoprazole Sodium in 0.9% Sodium Chloride Injection, 80mg / 100mL (0.8mg / mL) Single-Dose Infusion Bag in 100mL GALAXY Plastic Container, Frozen Premix	NC194129	5/7/2028	0338-9648-12
2G3592	Vancomycin Injection, USP in 0.9% Sodium Chloride, 1g/200 mL in GALAXY Plastic Container. Frozen Premix	NC193894	4/25/2027	0338-3583-01
2G3594	Daptomycin in 0.9% Sodium Chloride Injection, 500mg / 50 mL (10mg / mL), Single-Dose Infusion Bag in 50mL GALAXY plastic container (24 bags / carton). Frozen Premix.	NC188692	11/22/2027	0338-0714-24
2G3596	Daptomycin in 0.9% Sodium Chloride Injection, 1,000mg / 100 mL (10mg / mL), Single-Dose Infusion Bag in 100mL GALAXY Plastic Container. Frozen Premix.	NC193856	4/18/2028	0338-0718-12


Attachment B: Affected Product Label Photos



Product Code 2G3322 Label




Product Code 2G3424 Label




Product Code 2G3444 Label




Product Code 2G3450 Label




Product Code 2G3453 Label




Product Code 2G3454 Label



Product Code 2G3456 Label




Product Code 2G3459 Label




Product Code 2G3467 Label


Attachment B: Affected Product Label Photos




Product Code 2G3497 Label



Product Code 2G3498 Label




Product Code 2G3499 Label



Product Code 2G3552 Label



Product Code 2G3581 Label



Product Code 2G3592 Label



Product Code 2G3594 Label



Product Code 2G3596 Label

Baxter, Galaxy, Myxredlin, and Nexterone are trademarks of Baxter International Inc. or its subsidiaries.

Cardene is a registered trademark of Chiesi USA, Inc. and is used under license.

Novapilus is registered trademark of Vizient, Inc.

PREMIERProRx is a registered trademark of Premier Healthcare Alliance, L.P., used under license.

FA-2026-032